Background: Given the scarcity of real-world evidence on long-term effectiveness, this study assessed the effect of a once-weekly injectable formulation of semaglutide type 2 diabetes (sema OW T2D) on HbA1c and weight outcomes in individuals with T2D.

Methods: This retrospective database study included adults with T2D and HbA1c ≥7%, initiating sema OW T2D from January 2018 to September 2021, using linked data from IQVIA’s Longitudinal Prescription Claims, Professional Fee Claims, and Ambulatory Electronic Medical Records in the US. Descriptive and bivariate analyses were conducted to evaluate pre- and post-index (12 months) changes in HbA1c and weight-related outcomes.

Results: Among the final sample of 1,926 patients, mean HbA1c decreased significantly from 8.9% to 7.6% (p<0.001), with 40.2% of patients achieving HbA1c <7.0% over 12 months post-index. Mean weight decreased from 106.3 to 102.2 kg (p<0.001), with 37.9% and 13.3% of patients experiencing a ≥5% and ≥10% decrease in weight, respectively. Mean BMI decreased from 36.5 to 35.0 kg/m2 (p<0.001), with the proportion of patients with BMI ≥40.0 kg/m2 and BMI ≥30.0 kg/m2 decreasing from 29.2% to 24.4% and 81.1% to 73.6%, respectively.

Conclusion: At 12-month follow-up, adults with T2D initiating sema OW T2D had statistically significant decreases in HbA1c, weight, and BMI.


J. Amamoo: None. R. P. Doshi: Employee; IQVIA Inc. J. Noone: Employee; Novo Nordisk. X. Tan: Employee; Merck & Co., Inc., Novo Nordisk, Stock/Shareholder; Merck & Co., Inc., Novo Nordisk. L. Xie: Employee; Pfizer Inc., Novo Nordisk A/S. C. L. Gamble: Employee; Novo Nordisk. M. Guevarra: Employee; Novo Nordisk. J. Chen: Employee; IQVIA Inc. A. A. King: Advisory Panel; Novo Nordisk, Board Member; JDRF, Speaker's Bureau; Sanofi, Abbott, Dexcom, Inc., Lilly Diabetes.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at